Diagnostic Delay in Diffuse Large B-Cell Lymphoma Linked to Poorer Outcomes for Patients With Worse Disease
Researchers evaluated whether time to diagnosis of diffuse large B-cell lymphoma was associated with prognosis and survival.
Non-Hodgkin Lymphoma
FDA Greenlights New Rituxan Biosimilar
This US FDA has approved Ruxience for the treatment of adult patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.
Risk of Developing Certain Second Cancers May Vary According to non-Hodgkin Lymphoma Subtype
A retrospective study sought to determine the risk of solid-tumor second malignancy associated with an infectious etiology for patients with certain lymphomas or leukemias.
Increased Risk for Second Malignancy After Multiple Lines of Treatment in Follicular Lymphoma
Risk for malignancy was increased in patients who underwent 2 or 3 lines of treatment compared with patients who only underwent 1 line of treatment.
Response Patterns After Multiple Lines of Therapy in Mantle Cell Lymphoma
Early failure after treatment, old age, and treatment regimens not including stem cell transplantation were associated with poorer survival.
Number of Comorbidities Linked to Risk of Thromboembolism in Leukemia, Lymphoma
A retrospective study sought to determine the risk factors for thromboembolism in patients with acute leukemia or lymphoma.
Autologous Stem Cell Transplantation Outcomes in Patients With Peripheral T-Cell Lymphomas
Patients with higher International Prognostic Index scores or advanced-stage disease experienced improved survival when treated with ASCT.
Patients With NHL More Likely to Die of Cardiovascular Disease Compared With General Population
In this retrospective study, age-specific risk of death from cardiovascular disease was 14-fold higher in patients with NHL compared with the general population.
A Retrospective Look at Drug Sensitivity Before and After Checkpoint Blockade in R/R NHL
Checkpoint-based therapies may sensitize patients to subsequent therapies.
The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
[Cancer Management and Research] Researchers sought to determine the effect of intravenous hydration on plasma methotrexate clearance on pediatric oncology patients receiving HD-MTX for ALL, NHL, or osteosarcoma.
Next post in General Oncology
